
Energy (Manufacturing)
We work with manufacturers to address the increasingly complex energy manufacturing marketplace. With boots on the ground in a myriad of jurisdictions, we assist our clients across a their spectrum of need: from the implications of changing regulations on strategy, to managing risk when integrating new technology and process; from incident handling protocols and response readiness to investigations to strategies for negotiating the changing realities of global supply chain management.
Our deep understanding of the evolving energy landscape provides us with the necessary tools to help all types of manufacturing clients better manage energy and resource costs. Whether hedging against rising commodity costs, securing power supply on-site, or meeting new sustainability targets by transitioning to renewable power, our team can assist manufacturers in developing and implementing energy and commodity consumption strategies.
Thought Leadership
On February 28, 2019, the staff of the Division of Investment Management of the U.S.
On 23 December 2020, Judge Catherine Blake of the U.S. District Court for the District of Maryland granted the Pharmaceutical Research and Manufacturers of America (PhRMA) a 14-day nationwide temporary restraining order, preventing the Centers for Medicare and Medicaid Services (CMS) from implementing and enforcing its Most Favored Nation (MFN) interim final rule (MFN Rule) scheduled to take effect on 1 January 2021.
Following earlier announcements as to the efficacy of vaccine trials by pharmaceutical companies Pfizer, Inc. (Pfizer) and Moderna, Inc. on November 20, 2020, Pfizer and BioNTech submitted applications for emergency use authorization to the U.S. Food and Drug Administration (FDA) for their COVID-19 vaccinations.
This alert provides a brief overview of the final rules and the potential policy tools available to the Biden administration should it seek to revisit them.